FDA And CMS Agree To Share Data Routinely In Step Toward Parallel Reviews
This article was originally published in The Gray Sheet
Executive Summary
Routine sharing of data between FDA and CMS will be possible for the first time under a June 23 memorandum of understanding that could serve as a first step toward parallel reviews for marketing approval and Medicare coverage
You may also be interested in...
CMS Restricts Coverage For Devices More Than Drugs, Study Finds
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.
CMS Restricts Coverage For Devices More Than Drugs, Study Finds
Discrepancies between FDA-approved labeling and national Medicare coverage decisions are frequent, particularly for medical devices, where CMS tends to be more restrictive than FDA, researchers reported in Health Affairs. The findings have implications for the parallel review program.
Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS
The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.